title: Toll-like Receptors in Ovarian Cancer as Targets for Immunotherapies.
abstract: In the last decade, it has become apparent that toll-like receptor (TLR) signaling can play an important role in ovarian cancer (OC) progression. Interestingly, TLR activation in immune cells can help activate an anti-tumor response, while TLR signaling in tumor cells themselves is often associated with cancer-promoting inflammation. For example, it has been shown that TLR activation in dendritic cells can result in more effective antigen presentation to T cells, thereby favoring tumor eradication. However, aberrant TLR expression in OC cells is associated with more aggressive disease (likely due to recruitment of pro-tumoral leukocytes to the tumor site) and has also been implicated in resistance to mainstream chemotherapy. The delicate balance of TLR activation in the tumor microenvironment in different cell types altogether help shape the inflammatory profile and outcome of tumor growth or regression. With further studies, specific activation or repression of TLRs may be harnessed to offer novel immunotherapies or adjuvants to traditional chemotherapy for some OC patients. Herewith, we review recent literature on basic and translational research concerning therapeutic targeting of TLR pathways for the treatment of OC.
authors.affiliation: Molecular and Cell Biology Program, Ohio University , Athens, OH , USA.
authors.forename: Maria
authors.initials: M
authors.lastname: Muccioli
authors.affiliation: Molecular and Cell Biology Program, Ohio University , Athens, OH , USA ; Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University , Athens, OH , USA.
authors.forename: Fabian
authors.initials: F
authors.lastname: Benencia
keywords: immunotherapy; ovarian cancer; pattern-recognition receptors; toll-like receptors; tumor microenvironment
references.citation: Cancer Res. 2009 Sep 15;69(18):7329-37
references.pmid: 19738057
references.citation: Cancer Immunol Immunother. 2008 Sep;57(9):1271-8
references.pmid: 18256828
references.citation: Cancer Res. 2006 Apr 1;66(7):3859-68
references.pmid: 16585214
references.citation: Clin Pharmacol. 2013 May 23;5:13-9
references.pmid: 23723721
references.citation: Nat Rev Cancer. 2009 Jun;9(6):415-28
references.pmid: 19461667
references.citation: Am J Reprod Immunol. 2007 Feb;57(2):93-107
references.pmid: 17217363
references.citation: N Engl J Med. 2004 Dec 9;351(24):2519-29
references.pmid: 15590954
references.citation: Clin Cancer Res. 2001 Aug;7(8):2168-81
references.pmid: 11489790
references.citation: Cancer Res. 2010 Jan 15;70(2):490-500
references.pmid: 20068181
references.citation: Cell. 2010 Mar 19;140(6):883-99
references.pmid: 20303878
references.citation: Mol Med. 2008 Jul-Aug;14(7-8):476-84
references.pmid: 18431461
references.citation: Oncologist. 2008 Aug;13(8):859-75
references.pmid: 18701762
references.citation: J Immunol. 2008 Jul 1;181(1):22-6
references.pmid: 18566366
references.citation: Science. 2011 Mar 25;331(6024):1565-70
references.pmid: 21436444
references.citation: J Leukoc Biol. 2006 Oct;80(4):682-4
references.pmid: 16849612
references.citation: Cancer Sci. 2010 Apr;101(4):1059-66
references.pmid: 20156214
references.citation: Oncogene. 2008 Jan 7;27(2):225-33
references.pmid: 18176604
references.citation: J Transl Med. 2013 Jun 13;11:147
references.pmid: 23763830
references.citation: Cancer Res. 2005 Jun 15;65(12):5009-14
references.pmid: 15958541
references.citation: Clin Cancer Res. 2012 Jan 15;18(2):499-509
references.pmid: 22128302
references.citation: Annu Rev Immunol. 2003;21:335-76
references.pmid: 12524386
references.citation: Clin Cancer Res. 2011 Jul 15;17(14):4844-53
references.pmid: 21632857
references.citation: Nat Immunol. 2001 Aug;2(8):675-80
references.pmid: 11477402
references.citation: Cancer Immunol Immunother. 2010 Dec;59(12):1877-1884
references.pmid: 20820775
references.citation: Nat Med. 2004 Sep;10(9):950-8
references.pmid: 15334073
references.citation: Target Oncol. 2012 Mar;7(1):29-54
references.pmid: 22399234
references.citation: J Leukoc Biol. 2006 Oct;80(4):685-90
references.pmid: 16864602
references.citation: Front Oncol. 2014 Apr 07;4:72
references.pmid: 24778991
references.citation: Br J Cancer. 2006 Aug 7;95(3):247-52
references.pmid: 16892041
references.citation: Cancer Immunol Immunother. 2009 Sep;58(9):1375-85
references.pmid: 19184006
references.citation: Endocr Rev. 2001 Apr;22(2):255-88
references.pmid: 11294827
references.citation: Eur J Immunol. 2003 Jul;33(7):1767-75
references.pmid: 12811836
references.citation: Nat Rev Cancer. 2002 Apr;2(4):301-10
references.pmid: 12001991
references.citation: Blood. 2005 Jan 15;105(2):679-81
references.pmid: 15358628
references.citation: Cancer Microenviron. 2009 Sep;2 Suppl 1:205-14
references.pmid: 19685283
references.citation: Cell Cycle. 2010 Jan 15;9(2):260-8
references.pmid: 20023378
references.citation: Biochem Biophys Res Commun. 2011 Jun 17;409(4):675-80
references.pmid: 21616060
references.citation: J Cell Mol Med. 2010 Nov;14(11):2592-603
references.pmid: 20629986
references.citation: Vaccine. 2005 Mar 18;23(17-18):2374-8
references.pmid: 15755631
references.citation: J Leukoc Biol. 2008 May;83(5):1174-80
references.pmid: 18252871
references.citation: Oncogene. 2008 Aug 7;27(34):4712-23
references.pmid: 18408758
references.citation: Nat Rev Cancer. 2012 Mar 15;12(4):298-306
references.pmid: 22419253
references.citation: Cancer Res. 2010 May 15;70(10):4005-14
references.pmid: 20424119
references.citation: Nat Rev Cancer. 2006 Jan;6(1):24-37
references.pmid: 16397525
references.citation: J Transl Med. 2011 Dec 16;9:216
references.pmid: 22176642
references.citation: Semin Immunol. 2004 Feb;16(1):3-9
references.pmid: 14751757
references.citation: J Exp Med. 2012 Mar 12;209(3):495-506
references.pmid: 22351930
references.citation: Science. 2005 Aug 26;309(5739):1380-4
references.pmid: 16123302
references.citation: Hum Gene Ther. 2009 Apr;20(4):303-13
references.pmid: 19272013
references.citation: Oncogene. 2008 Jan 7;27(2):218-24
references.pmid: 18176603
references.citation: Int Immunopharmacol. 2007 Oct;7(10):1271-85
references.pmid: 17673142
references.citation: Eur J Immunol. 2014 Jun;44(6):1814-22
references.pmid: 24510590
references.citation: Nat Rev Immunol. 2011 Mar;11(3):163-75
references.pmid: 21331081
references.citation: Cancer. 2010 Jul 1;116(13):3276-84
references.pmid: 20564628